Sina Nassiri
Sina Nassiri has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Emilio Yángüez
Roche Innovation Center Zurich, Schlieren, Switzerland
94 shared publications - Christian Klein
Faculty for Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
93 shared publications - Gabrielle Leclercq-Cohen
Roche Innovation Center Zurich, Zurich, Switzerland
93 shared publications - Johannes Sam
Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland
93 shared publications - Marina Bacac
Roche Innovation Center Zurich, Schlieren, Switzerland
93 shared publications - Pablo Umaña
Roche Innovation Center Zurich, Schlieren, Switzerland
93 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014620
FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge for immunotherapy due to its immunologically cold tumor nature, characterized by poor T cell infiltration and a highly suppressive tumor microenvironment. Here, we propose a novel strategy, combining fibroblast activation protein (FAP)-CD40 to activate dendritic cells (DCs) in the tumor microenvironment and programmed cell death protein-1 (PD1)-interleukin 2v (IL2v) to promote the expansion and differentiation of tumor-infiltrating T cells. We hypothesize that this combination will synergistically enhance both T cell priming and expansion directly within pancreatic 4662 KPC tumors, which recapitulate the immunologically cold features of human PDAC. Methods: Immune cell distribution and abundance following FAP-CD40/PD1-IL2v monotherapy or combination therapy were analyzed using multiplexed confocal imaging (3D immune phenotyping). FTY720 studies assessed the contribution of lymph node priming in treatment efficacy, while CD4+/CD8+ T cell depletion experiments identified the roles of these subsets in combination therapy. T cell functionality was further assessed through ex vivo restimulation assays and single-cell RNA sequencing. Results: Combination therapy induced dense intratumoral clusters of CD4 + and CD8 + T cells, colocalized with type 1 conventional DCs, termed as T cell-DC clusters (TDCs). These TDCs were strongly associated with tumor regression, which required both CD4 + and CD8 + T cells. Furthermore, T cells from combination-treated tumors showed enhanced functionality, with increased tumor necrosis factor-alpha and interferon-gamma production compared with monotherapy groups. Single-cell RNA sequencing revealed polarization of CD4 + T cells toward a T helper cell 1 phenotype in combination-treated tumors. Conclusion: The combination of FAP-CD40 and PD1-IL2v offers a promising strategy for treating poorly infiltrated, cold tumors. By driving T cell infiltration, promoting de novo TDC formation and orchestrating local antitumor immunity, this strategy provides a foundation for future therapies targeting immunotherapy-resistant tumors.
- 28 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014620
Open AccessFAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge for immunotherapy due to its immunologically cold tumor nature, characterized by poor T cell infiltration and a highly suppressive tumor microenvironment. Here, we propose a novel strategy, combining fibroblast activation protein (FAP)-CD40 to activate dendritic cells (DCs) in the tumor microenvironment and programmed cell death protein-1 (PD1)-interleukin 2v (IL2v) to promote the expansion and differentiation of tumor-infiltrating T cells. We hypothesize that this combination will synergistically enhance both T cell priming and expansion directly within pancreatic 4662 KPC tumors, which recapitulate the immunologically cold features of human PDAC. Methods: Immune cell distribution and abundance following FAP-CD40/PD1-IL2v monotherapy or combination therapy were analyzed using multiplexed confocal imaging (3D immune phenotyping). FTY720 studies assessed the contribution of lymph node priming in treatment efficacy, while CD4+/CD8+ T cell depletion experiments identified the roles of these subsets in combination therapy. T cell functionality was further assessed through ex vivo restimulation assays and single-cell RNA sequencing. Results: Combination therapy induced dense intratumoral clusters of CD4 + and CD8 + T cells, colocalized with type 1 conventional DCs, termed as T cell-DC clusters (TDCs). These TDCs were strongly associated with tumor regression, which required both CD4 + and CD8 + T cells. Furthermore, T cells from combination-treated tumors showed enhanced functionality, with increased tumor necrosis factor-alpha and interferon-gamma production compared with monotherapy groups. Single-cell RNA sequencing revealed polarization of CD4 + T cells toward a T helper cell 1 phenotype in combination-treated tumors. Conclusion: The combination of FAP-CD40 and PD1-IL2v offers a promising strategy for treating poorly infiltrated, cold tumors. By driving T cell infiltration, promoting de novo TDC formation and orchestrating local antitumor immunity, this strategy provides a foundation for future therapies targeting immunotherapy-resistant tumors.
- Open Access
- 30 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 2977-2990
Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma
T-cell engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment. In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (peripheral blood mononuclear cells [PBMCs]) from patients with glofitamab-treated R/R B-NHL, achieving complete metabolic response, or with progressive metabolic disease. Our findings reveal that the maintenance of naïve-like (“fresher”) T-cell states (particularly the fresher cytotoxic T cells) at early time points is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared with nonresponders. Furthermore, the analysis of patient PBMCs and intratumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB costimulation translated into increased proportions of intratumor T cells having a fresher, naïve-like phenotype, ultimately leading to stronger antitumor efficacy. Taken together, our findings underscore the therapeutic relevance of fresher, naïve-like T-cell states and the potential of leveraging 4-1BB costimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.
- 30 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 2977-2990
Open AccessMolecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma
T-cell engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment. In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (peripheral blood mononuclear cells [PBMCs]) from patients with glofitamab-treated R/R B-NHL, achieving complete metabolic response, or with progressive metabolic disease. Our findings reveal that the maintenance of naïve-like (“fresher”) T-cell states (particularly the fresher cytotoxic T cells) at early time points is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared with nonresponders. Furthermore, the analysis of patient PBMCs and intratumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB costimulation translated into increased proportions of intratumor T cells having a fresher, naïve-like phenotype, ultimately leading to stronger antitumor efficacy. Taken together, our findings underscore the therapeutic relevance of fresher, naïve-like T-cell states and the potential of leveraging 4-1BB costimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S10. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S10. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S3. Identification of an interacting B and T cells cluster by scRNA sequencing of human whole blood treated with 0.2 μg/mL CD20-TCB using the BD Rhapsody platform.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S3. Identification of an interacting B and T cells cluster by scRNA sequencing of human whole blood treated with 0.2 μg/mL CD20-TCB using the BD Rhapsody platform.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S8. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S8. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S12. Individual tumor growth curves for each treatment group. OCI-Ly18 (DLBCL)-bearing humanized NSG mice were pre-treated with 30 mg/kg Gazyva (Gpt, grey arrow) and treated weekly with escalating doses of CD20-TCB (0.5 mg/kg, 1 mg/kg, 2 mg/kg, red arrows). Adalimumab (25 mg/kg, orange arrow, TNF-α blockade) and tocilizumab (10 mg/kg, green arrow, IL-6R blockade) were given 1 day and 1 hour before the first CD20-TCB infusion. Dexamethasone (1 mg/kg, blue arrow) was given 1 hour prior each therapy. Anakinra (10 mg/kg, purple arrow, IL-1R blockade) and the NLRP3 inhibitor (20 mg/kg, light blue arrow) were administered 1 hour before, 4 hrs and 24 hrs after the first CD20-TCB infusion as well as 1 hr before and 4 hrs after the second CD20-TCB treatment. Individual tumor growth curves for each treatment group.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S12. Individual tumor growth curves for each treatment group. OCI-Ly18 (DLBCL)-bearing humanized NSG mice were pre-treated with 30 mg/kg Gazyva (Gpt, grey arrow) and treated weekly with escalating doses of CD20-TCB (0.5 mg/kg, 1 mg/kg, 2 mg/kg, red arrows). Adalimumab (25 mg/kg, orange arrow, TNF-α blockade) and tocilizumab (10 mg/kg, green arrow, IL-6R blockade) were given 1 day and 1 hour before the first CD20-TCB infusion. Dexamethasone (1 mg/kg, blue arrow) was given 1 hour prior each therapy. Anakinra (10 mg/kg, purple arrow, IL-1R blockade) and the NLRP3 inhibitor (20 mg/kg, light blue arrow) were administered 1 hour before, 4 hrs and 24 hrs after the first CD20-TCB infusion as well as 1 hr before and 4 hrs after the second CD20-TCB treatment. Individual tumor growth curves for each treatment group.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S5. Overview of GO Biological process pathways found enriched in A. CD4+ T cells (6 hrs), B. CD8+ T cells (6 hrs), C. monocytes (6 hrs) and D. neutrophils (4 hrs) after treatment with 0.2 μg/mL CD20-TCB.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S5. Overview of GO Biological process pathways found enriched in A. CD4+ T cells (6 hrs), B. CD8+ T cells (6 hrs), C. monocytes (6 hrs) and D. neutrophils (4 hrs) after treatment with 0.2 μg/mL CD20-TCB.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S1. Levels of cytokines were measured by Luminex in serum from whole blood assay with CD20-TCB. 1 donor.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S1. Levels of cytokines were measured by Luminex in serum from whole blood assay with CD20-TCB. 1 donor.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S2. Proportions of T cells, monocytes and neutrophils in human whole blood after treatment with 0.2 μg/mL CD20-TCB
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Figure S2. Proportions of T cells, monocytes and neutrophils in human whole blood after treatment with 0.2 μg/mL CD20-TCB
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Table S1. Specification of reagents for flow cytometry (Whole Blood Assay)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Supplementary Table S1. Specification of reagents for flow cytometry (Whole Blood Assay)